Brainstorm cell therapeutics announces appointment of haro hartounian ph.d. as chief operating officer

Appointment completes executive readiness for registrational phase 3b als study launch new york , june 20, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of hartoun hartounian ph.d. as its new evp and coo, effective as of june 18, 2024.
BCLI Ratings Summary
BCLI Quant Ranking